吉林敖東(000623.SZ)擬500萬美元對Hinova進行股權投資
格隆匯12月20日丨吉林敖東(000623.SZ)公佈，公司於2019年12月20日召開第九屆董事會第十九次會議審議通過了《關於對外投資的議案》，根據公司戰略發展規劃，公司擬以500萬美元對Hinova Pharmaceuticals,Inc.(“Hinova”)進行股權投資。
公司於2019年12月20日與Hinova等簽訂了《SERIES B PREFERRED SHARES PURCHASE AGREEMENT》，根據協議，公司以自有資金500萬美元按每股2.28494美元的價格認購218.8244萬股Hinova發行的B輪優先股，佔Hinova總股本的1.57%。
Hinova Pharmaceuticals, Inc.是一家根據開曼羣島法律正式註冊成立的獲豁免公司(exempted company), 在美國、澳大利亞等地設有分支機構，其全資子公司成都海創藥業有限公司(“海創藥業”)是一家總部坐落於中國成都，面向海外和中國市場開展新藥研究及產業化的創新藥物企業，海創藥業是國家高新技術企業。海創藥業依託全球領先的氘代、PROTAC、前列腺癌症藥物研發等技術平台，開發具有廣闊市場潛力的重大新藥品種，目前有包括治療前列腺腫瘤、乳腺腫瘤、胰腺癌、痛風等疾病的多個創新藥物正處於臨牀和臨牀前的不同研究階段。
海創藥業已建立了包括藥物化學、生物篩選、工藝研究、質量研究、註冊申報、中國和全球臨牀研究、生產外包等完整藥物研發和產業化體系。海創藥業現有產品管線中，HC-1119(治療去勢抵抗性前列腺癌新藥)已獲得中國NMPA和美國FDA批准進入III期臨牀試驗並正在進行中。HP501(治療高尿酸血癥/痛風新藥)已於2018年11月獲得NMPA頒發的《臨牀試驗通知書》，正在四川大學華西醫院開展臨牀I期試驗。海創藥業組建了來自世界500強企業和頂尖院所的12位海歸和海外專家組成的核心管理團隊，現已申請PCT和中國發明專利逾100項，獲得中國、美國、日本、歐洲等國家和地區專利授權近30餘項。
公司此次對外投資Hinova目的主要是對Hinova所屬集團新藥研發能力的認可，Hinova子公司海創藥業及其關聯公司自主研發的前列腺癌藥物HC-1119的研發能力較強、研發經驗豐富，有利於公司加強同創新藥物研發平台的研究與合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
